Vlado Perkovic's Publications

About Vlado Perkovic's Publications

Board Member
  • MBBS,
  • PhD,
  • FASN,
  • FRACP

  • Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials

    The Lancet Diabetes & Endocrinology Date published:

  • Relationship of Estimated GFR and Albuminuria to Concurrent Laboratory Abnormalities: An Individual Participant Data Meta-analysis in a Global Consortium

    American Journal of Kidney Diseases Date published:

  • Canagliflozin and Stroke in Type 2 Diabetes Mellitus

    Stroke Date published:

  • Linagliptin Effects on Heart Failure and Related Outcomes in Individuals With Type 2 Diabetes Mellitus at High Cardiovascular and Renal Risk in CARMELINA

    Circulation Date published:

  • Proteinuria Reduction as a Surrogate End Point in Trials of IgA Nephropathy

    Clinical Journal of the American Society of Nephrology Date published:

  • Adiposity and risk of decline in glomerular filtration rate: meta-analysis of individual participant data in a global consortium

    BMJ Date published:

  • Canagliflozin Reduces Cardiovascular and Renal Events in Patients With Type 2 Diabetes and Chronic Kidney Disease Regardless of Baseline HbA1c, Including Those With HbA1c < 7%: Results From the CREDENCE Trial

    Date published:

  • First plus recurrent CV and hospitalization events in the CArdiovascular and Renal Microvascular outcomE study with LINAgliptin (CARMELINA) in patients with type 2 diabetes and cardiorenal disease

    Date published:

  • Interrelationship between hypoglycemia and CV and mortality outcomes in type 2 diabetes in the CARMELINA Trial

    Date published:

  • SGLT2 inhibitor lowers risk of kidney failure in type 2 diabetes

    Pharmaceutical Journal Date published:

  • Randomised controlled trial of the impact of haemodiafiltration on uraemic neuropathy: FINESSE study protocol

    BMJ Open Date published:

  • Acute Increases in Serum Creatinine After Starting Angiotensin-Converting Enzyme Inhibitor-Based Therapy and Effects of its Continuation on Major Clinical Outcomes in Type 2 Diabetes Mellitus

    Hypertension Date published:

  • Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk

    JAMA Date published:

  • China Kidney Disease Network (CK-NET) 2015 Annual Data Report

    Kidney International Supplements Date published:

  • Implementing core outcomes in kidney disease: report of the Standardized Outcomes in Nephrology (SONG) implementation workshop

    Kidney International Date published:

  • Efficacy of a novel inhibitor of vascular adhesion protein-1 in reducing albuminuria in patients with diabetic kidney disease (ALBUM): a randomised, placebo-controlled, phase 2 trial

    The Lancet Diabetes & Endocrinology Date published: